Martin H. Voss, MD, on Bringing Different Disciplines Together at IKCS

Article

The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.

Martin H. Voss, MD, from Memorial Sloan Kettering Cancer Center, discussed the various talks being presented at the International Kidney Cancer Symposium, held November 15-16, in Miami.

Transcription:
I’m excited to see new therapeutic strategies being discussed and I think this meeting has come a long way to actually bring different disciplines together. So, you know, we will be seeing the discussion of new targets in terms of new clinical data, but there’s also great talks that I’ve been looking forward to from laboratory investigators telling us about their efforts identifying new targets from a basic science perspective.

Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Related Content